Purchase Order 75N91019P00060

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for extended warranty services valued at $3,004.32 on February 20, 2020, with an ultimate completion date of February 28, 2021. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation. This purchase order was issued to de-obligate fiscal year 2020 expiring lines per NIH OALM communication 25-06.</p>

The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $22,504.00 on March 1, 2018, with a completion date of August 31, 2018. The order is a firm fixed price, commercial acquisition with no small business set-aside. Performance takes place in Bethesda, Maryland. The procurement covers specialized life sciences equipment, instrumentation, or related services aligned with Acea's portfolio of flow cytometry, cell analysis, and biosensing products for research...

<p>The National Cancer Institute issued a purchase order to Acea Biosciences, Inc. on June 27, 2019 for maintenance agreement services with a ceiling value of $15,627.60 and an ultimate completion date of June 29, 2020. Place of performance is San Diego, California. The order was awarded under firm fixed price on a no-set-aside basis.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,480.00 on May 22, 2020, with completion scheduled for June 29, 2021. Work is performed in San Diego, California. The order is firm fixed price with no set-aside designation. Acea Biosciences is a subsidiary of Agilent Technologies and supplies life sciences instrumentation, software, consumables, and services to federal research organizations.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. valued at $4,275.00 on February 5, 2020, for a service agreement to de-obligate expiring FY20 lines. Work is performed at Bethesda, Maryland. The order carries firm fixed pricing and completed on February 28, 2021. No set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $2,916.59 on July 1, 2014, for preventative maintenance service on an Xcelligence DP invasion machine (Serial # 32-1110-1728-7). Performance is in Bethesda, Maryland, with completion by June 30, 2015. The order was placed under firm fixed-price terms with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $32,593.00 on August 7, 2019, for in vitro testing of anti-cancer therapeutics using Xcelligence technology. Work is performed in San Diego, California. The order is firm fixed price with an ultimate completion date of September 6, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. on June 8, 2026, for maintenance services on Novocyte 3000 and NovoSampler Pro equipment, valued at $17,520.00, with a completion date of June 7, 2027. Work is performed in Bethesda, Maryland. The contract is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,627.60 on June 29, 2017, with completion by June 30, 2018. No set-aside applies. Work is performed in San Diego, California. The order covers life sciences instrumentation, software, services, consumables, and expertise related to flow cytometry and cell analysis technology, priced on a firm fixed price basis.</p>

This one-year firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Child Health and Human Development to Acea Biosciences, Inc., a for-profit life sciences company that is a subsidiary of Agilent Technologies. The $8,705.70 contract is for an extended service warranty on a NovoCyte One laser system, which was likely procured by the NIH to support specialized research and testing. Acea Biosciences has...